利妥昔单抗治疗后B细胞清除程度可预测IgG4相关性疾病复发
这项回顾性研究纳入33例符合ACR/EULAR分类标准的活动性IgG4相关性疾病患者,均接受两剂1 g利妥昔单抗(间隔15天)并随访48个月。利妥昔单抗后6个月未完全清除CD19+ B细胞、初始B细胞或记忆B细胞的患者复发率显著更高、无复发生存期更短,提示6个月时B细胞清除程度可能预测疾病复发并指导B细胞清除治疗的节奏。
要点
- 33例活动性IgG4-RD患者接受两剂1 g利妥昔单抗(间隔15天),随访48个月。
- 23例(70%)复发,中位复发时间为利妥昔单抗后24个月。
- 6个月时未完全清除CD19+ B细胞、初始B细胞或记忆B细胞者复发率显著更高、无复发生存期更短。
核心结论
- 利妥昔单抗后6个月B细胞清除程度可能预测IgG4相关性疾病复发,并可能指导B细胞清除治疗的节奏。
研究设计与样本
- 回顾性研究,纳入33例符合ACR/EULAR分类标准的活动性IgG4相关性疾病患者。
- 所有患者接受两剂1 g利妥昔单抗输注、间隔15天,并随访48个月。
- 基线及利妥昔单抗后6个月采用流式细胞术检测外周血总CD19+ B细胞、浆母细胞、初始B细胞和记忆B细胞。
- 疾病反应采用IgG4-RD Responder Index评估。
主要发现
- 利妥昔单抗后6个月全部患者均观察到疾病反应。
- CD19+ B细胞、浆母细胞、初始B细胞和记忆B细胞完全清除分别见于30%、55%、39%和42%的病例。
- 随访中观察到23例复发(70%),中位复发时间为利妥昔单抗后24个月。
- 6个月时未完全清除CD19+ B细胞者复发率为60%,完全清除者为17%(P = 0.02)。
- 6个月时未完全清除初始B细胞者复发率为54%,完全清除者为15%(P = 0.01);未完全清除记忆B细胞者复发率为50%,完全清除者为16%(P = 0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: B cell depletion therapy with rituximab is effective in most patients with IgG4-related disease (IgG4-RD) but requires repeated cycles to prevent disease flares. We here aimed to assess B cells after rituximab to predict relapse of IgG4-RD and guide retreatment. METHODS: Patients with active IgG4-RD included in this retrospective study fulfilled the ACR/EULAR Classification Criteria. Total CD19+ B cells, plasmablasts, naïve and memory B cells were measured on peripheral blood by flow-cytometry at baseline and 6 months after rituximab. All patients were treated with two 1 g infusions of rituximab 15 days apart and monitored for 48 months. Disease response was assessed using the IgG4-RD Responder Index. RESULTS: Thirty-three patients were included. Six months after rituximab, disease response was observed in all patients. Complete depletion of CD19+ B cells, plasmablasts, naïve and memory B cell depletion was achieved in 30%, 55%, 39% and 42% of cases, respectively. Twenty-three relapses (70%) were observed at a median time of 24 months after rituximab. Relapse rate was significantly higher in patients who failed to achieve complete depletion of CD19+ cells (60% vs 17%, P = 0.02), naïve B cells (54% vs 15%, P = 0.01), or memory B cells (50% vs 16%, P = 0.03) 6 months after rituximab. The median relapse free survival time was shorter in patients who failed to achieve complete depletion of CD19+ cells (19 vs 38 months, P = 0.02), naïve B cells (16 vs 38 months, P = 0.01), or memory B cells (19 vs 38 months, P = 0.03) 6 months after rituximab. CONCLUSION: The degree of B cell depletion 6 months after rituximab may predict disease flare and may instruct on the pacing of B cell depletion therapy in IgG4-RD.
引用
- Lanzillotta M, Ramirez GA, Milani R, et al. B cell depletion after treatment with rituximab predicts relapse of IgG4-related disease. Rheumatology (Oxford). 2025. PMID: 38781535. doi:10.1093/rheumatology/keae248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。